(BIRK) Birkenstock Holding - Overview
Stock: Sandals, Closed-Toe Shoes, Footbeds, Accessories, Skincare
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.5% |
| Relative Tail Risk | -7.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.94 |
| Alpha | -48.39 |
| Character TTM | |
|---|---|
| Beta | 1.076 |
| Beta Downside | 0.792 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.56% |
| CAGR/Max DD | -0.18 |
Description: BIRK Birkenstock Holding January 07, 2026
Birkenstock Holding plc (NYSE:BIRK) designs, manufactures, and sells footbed-based footwear-including sandals, closed-toe shoes, and related accessories-as well as a limited line of skincare products. The brand reaches customers worldwide through its own retail stores, e-commerce platforms, and B2B distribution channels, operating across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
In its latest FY2023 filing, Birkenstock reported revenue of roughly €1.6 billion, a 12 % year-over-year increase driven primarily by strong demand in the U.S. and Germany; e-commerce accounted for about 30 % of total sales, while gross margins stabilized near 55 % after a modest cost-inflation offset. The company’s operating cash flow turned positive at €180 million, supporting a dividend payout of €0.30 per share.
Key economic and sector drivers include (1) consumer discretionary spending trends in mature markets, where post-pandemic confidence is boosting premium-price footwear; (2) a growing sustainability premium, as Birkenstock’s natural-cork footbeds align with ESG-focused purchasing; and (3) supply-chain resilience, with the firm increasingly near-shoring production to mitigate raw-material price volatility. Any material slowdown in discretionary income or a sharp rise in raw-material costs could pressure margins.
For a deeper, data-rich analysis of Birkenstock’s valuation and risk profile, a quick look at ValueRay’s dashboard can help you surface the most relevant metrics.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 348.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.85 > 1.0 |
| NWC/Revenue: 46.03% < 20% (prev 39.58%; Δ 6.45% < -1%) |
| CFO/TA 0.07 > 3% & CFO 403.3m > Net Income 348.3m |
| Net Debt (1.19b) to EBITDA (696.9m): 1.70 < 3 |
| Current Ratio: 2.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (183.9m) vs 12m ago -2.09% < -2% |
| Gross Margin: 59.11% > 18% (prev 0.58%; Δ 5853 % > 0.5%) |
| Asset Turnover: 39.23% > 50% (prev 37.00%; Δ 2.23% > 0%) |
| Interest Coverage Ratio: 7.10 > 6 (EBITDA TTM 696.9m / Interest Expense TTM 81.4m) |
Altman Z'' 2.67
| A: 0.17 (Total Current Assets 1.50b - Total Current Liabilities 533.1m) / Total Assets 5.81b |
| B: 0.15 (Retained Earnings 899.9m / Total Assets 5.81b) |
| C: 0.11 (EBIT TTM 577.9m / Avg Total Assets 5.35b) |
| D: 0.33 (Book Value of Equity 858.2m / Total Liabilities 2.61b) |
| Altman-Z'' Score: 2.67 = A |
Beneish M -2.67
| DSRI: 1.35 (Receivables 222.5m/142.3m, Revenue 2.10b/1.81b) |
| GMI: 0.98 (GM 59.11% / 57.69%) |
| AQI: 0.98 (AQ_t 0.65 / AQ_t-1 0.66) |
| SGI: 1.16 (Revenue 2.10b / 1.81b) |
| TATA: -0.01 (NI 348.3m - CFO 403.3m) / TA 5.81b) |
| Beneish M-Score: -2.67 (Cap -4..+1) = A |
What is the price of BIRK shares?
Over the past week, the price has changed by +3.47%, over one month by -12.81%, over three months by -1.54% and over the past year by -31.92%.
Is BIRK a buy, sell or hold?
- StrongBuy: 15
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BIRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 58.5 | 52.2% |
| Analysts Target Price | 58.5 | 52.2% |
| ValueRay Target Price | 36.6 | -4.7% |
BIRK Fundamental Data Overview February 03, 2026
P/E Trailing = 16.7822
P/E Forward = 16.0
P/S = 3.3109
P/B = 2.1203
P/EG = 1.4686
Revenue TTM = 2.10b EUR
EBIT TTM = 577.9m EUR
EBITDA TTM = 696.9m EUR
Long Term Debt = 1.10b EUR (from longTermDebt, last quarter)
Short Term Debt = 60.7m EUR (from shortTermDebt, last quarter)
Debt = 1.31b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.19b EUR (from netDebt column, last quarter)
Enterprise Value = 6.84b EUR (5.87b + Debt 1.31b - CCE 340.8m)
Interest Coverage Ratio = 7.10 (Ebit TTM 577.9m / Interest Expense TTM 81.4m)
EV/FCF = 21.62x (Enterprise Value 6.84b / FCF TTM 316.5m)
FCF Yield = 4.63% (FCF TTM 316.5m / Enterprise Value 6.84b)
FCF Margin = 15.09% (FCF TTM 316.5m / Revenue TTM 2.10b)
Net Margin = 16.61% (Net Income TTM 348.3m / Revenue TTM 2.10b)
Gross Margin = 59.11% ((Revenue TTM 2.10b - Cost of Revenue TTM 857.7m) / Revenue TTM)
Gross Margin QoQ = 58.14% (prev 60.48%)
Tobins Q-Ratio = 1.18 (Enterprise Value 6.84b / Total Assets 5.81b)
Interest Expense / Debt = 0.97% (Interest Expense 12.7m / Debt 1.31b)
Taxrate = 7.37% (7.47m / 101.3m)
NOPAT = 535.3m (EBIT 577.9m * (1 - 7.37%))
Current Ratio = 2.81 (Total Current Assets 1.50b / Total Current Liabilities 533.1m)
Debt / Equity = 0.41 (Debt 1.31b / totalStockholderEquity, last quarter 3.20b)
Debt / EBITDA = 1.70 (Net Debt 1.19b / EBITDA 696.9m)
Debt / FCF = 3.75 (Net Debt 1.19b / FCF TTM 316.5m)
Total Stockholder Equity = 2.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.52% (Net Income 348.3m / Total Assets 5.81b)
RoE = 12.25% (Net Income TTM 348.3m / Total Stockholder Equity 2.84b)
RoCE = 14.66% (EBIT 577.9m / Capital Employed (Equity 2.84b + L.T.Debt 1.10b))
RoIC = 21.05% (NOPAT 535.3m / Invested Capital 2.54b)
WACC = 8.24% (E(5.87b)/V(7.18b) * Re(9.88%) + D(1.31b)/V(7.18b) * Rd(0.97%) * (1-Tc(0.07)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.05%
[DCF Debug] Terminal Value 80.47% ; FCFF base≈332.5m ; Y1≈410.2m ; Y5≈698.5m
Fair Price DCF = 54.73 (EV 11.25b - Net Debt 1.19b = Equity 10.07b / Shares 183.9m; r=8.24% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 51.15 | EPS CAGR: 8.84% | SUE: 4.0 | # QB: 2
Revenue Correlation: 63.49 | Revenue CAGR: 29.00% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.61 | Chg30d=-0.007 | Revisions Net=-6 | Analysts=17
EPS current Year (2026-09-30): EPS=2.03 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+9.9% | Growth Revenue=+11.7%
EPS next Year (2027-09-30): EPS=2.41 | Chg30d=-0.044 | Revisions Net=-4 | Growth EPS=+18.7% | Growth Revenue=+14.2%